ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclear
Johnson & Johnson’s Akeega is giving the PARP inhibitor class a first win in castration-sensitive prostate cancer, although the drug’s benefit in a patient subgroup remains unclear.
Johnson & Johnson’s Akeega is giving the PARP inhibitor class a first win in castration-sensitive prostate cancer, although the drug’s benefit in a patient subgroup remains unclear.
